Mimura N, Hideshima T, Anderson KC. Novel therapeutic strategies for multiple myeloma. Exp Hematol. 2015;43:732–41.
Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos MV, et al. Multiple myeloma. Nat Rev Disease Primers. 2017;3:17046.
Rasch S, Lund T, Asmussen JT, Lerberg Nielsen A, Faebo Larsen R, Østerheden Andersen M, et al. Multiple myeloma associated bone disease. Cancers. 2020;12:2113.
Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046–60.
Stewart AF. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med. 2005;352:373–9.
Zagouri F, Kastritis E, Zomas A, Terpos E, Katodritou E, Symeonidis A, et al. Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies. Eur J Haematol. 2017;99:409–14.
Oyajobi BO. Multiple myeloma/hypercalcemia. Arthritis Res Therapy. 2007;9(Suppl 1):S4.
Tuttle KR, Kunau RT, Loveridge N, Mundy GR. Altered renal calcium handling in hypercalcemia of malignancy. J Am Soc Nephrol. 1991;2:191–9.
Silver IA, Murrills RJ, Etherington DJ. Microelectrode studies on the acid microenvironment beneath adherent macrophages and osteoclasts. Exp Cell Res. 1988;175:266–76.
Cui C, Merritt R, Fu L, Pan Z. Targeting calcium signaling in cancer therapy. Acta pharmaceutica Sinica B. 2017;7:3–17.
Shoshan-Barmatz V, De S. Mitochondrial VDAC, the Na(+)/Ca(2+) exchanger, and the Ca(2+) uniporter in Ca(2+) dynamics and signaling. Adv Exp Med Biol. 2017;981:323–47.
Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70.
Bai H, Zhu H, Yan Q, Shen X, Lu X, Wang J, et al. TRPV2-induced Ca(2+)-calcineurin-NFAT signaling regulates differentiation of osteoclast in multiple myeloma. Cell Commun Signal. 2018;16:68.
Cao B, Dai X, Wang W. Knockdown of TRPV4 suppresses osteoclast differentiation and osteoporosis by inhibiting autophagy through Ca(2+) -calcineurin-NFATc1 pathway. J Cell Physiol. 2019;234:6831–41.
Farrell AW, Gadeock S, Pupovac A, Wang B, Jalilian I, Ranson M, et al. P2X7 receptor activation induces cell death and CD23 shedding in human RPMI 8226 multiple myeloma cells. Biochem Biophys Acta. 2010;1800:1173–82.
Wang W, Ren Y, Wang L, Zhao W, Dong X, Pan J, et al. Orai1 and stim1 mediate the majority of store-operated calcium entry in multiple myeloma and have strong implications for adverse prognosis. Cell Physiol Biochem: Int J Exp Cell Physiol Biochem Pharmacol. 2018;48:2273–85.
Liu S, Ishikawa H, Tsuyama N, Li FJ, Abroun S, Otsuyama KI, et al. Increased susceptibility to apoptosis in CD45(+) myeloma cells accompanied by the increased expression of VDAC1. Oncogene. 2006;25:419–29.
Wu LJ, Sweet TB, Clapham DE. International union of basic and clinical pharmacology. LXXVI. Current progress in the mammalian TRP ion channel family. Pharmacol Rev. 2010;62:381–404.
Clapham DE. SnapShot: mammalian TRP channels. Cell. 2007;129:220.
Minke B. TRP channels and Ca2+ signaling. Cell Calcium. 2006;40:261–75.
Taberner FJ, Devesa I, Ferrer-Montiel A. Calcium entry through thermosensory channels. Adv Exp Med Biol. 2016;898:265–304.
Eda H, Santo L, David Roodman G, Raje N. Bone disease in multiple myeloma. Cancer Treat Res. 2016;169:251–70.
Roodman GD. Targeting the bone microenvironment in multiple myeloma. J Bone Miner Metab. 2010;28:244–50.
Fabris S, Todoerti K, Mosca L, Agnelli L, Intini D, Lionetti M, et al. Molecular and transcriptional characterization of the novel 17p11.2-p12 amplicon in multiple myeloma. Genes Chromosomes Cancer. 2007;46:1109–18.
Krishnamoorthy M, Wasim L, Buhari FHM, Zhao T, Mahtani T, Ho J, et al. The channel-kinase TRPM7 regulates antigen gathering and internalization in B cells. Science signaling. 2018;11:eaah6692.
Launay P, Cheng H, Srivatsan S, Penner R, Fleig A, Kinet JP. TRPM4 regulates calcium oscillations after T cell activation. Science (New York, NY). 2004;306:1374–7.
van Goor MK, de Jager L, Cheng Y, van der Wijst J. High-resolution structures of transient receptor potential vanilloid channels: Unveiling a functionally diverse group of ion channels. Protein Sci: Publ Protein Soc. 2020;29:1569–80.
Clapham DE. TRP channels as cellular sensors. Nature. 2003;426:517–24.
Guarino BD, Paruchuri S, Thodeti CK. The role of TRPV4 channels in ocular function and pathologies. Exp Eye Res. 2020;201:108257.
Venkatachalam K, Montell C. TRP channels. Annu Rev Biochem. 2007;76:387–417.
van Goor MKC, Hoenderop JGJ, van der Wijst J. TRP channels in calcium homeostasis: from hormonal control to structure-function relationship of TRPV5 and TRPV6. Biochim Biophys Acta. 2017;1864:883–93.
Fleig A, Penner R. The TRPM ion channel subfamily: molecular, biophysical and functional features. Trends Pharmacol Sci. 2004;25:633–9.
Huang Y, Fliegert R, Guse AH, Lü W, Du J. A structural overview of the ion channels of the TRPM family. Cell Calcium. 2020;85:102111.
Launay P, Fleig A, Perraud AL, Scharenberg AM, Penner R, Kinet JP. TRPM4 is a Ca2+-activated nonselective cation channel mediating cell membrane depolarization. Cell. 2002;109:397–407.
Hofmann T, Chubanov V, Gudermann T, Montell C. TRPM5 is a voltage-modulated and Ca(2+)-activated monovalent selective cation channel. Current Biol: CB. 2003;13:1153–8.
Winter Z, Buhala A, Ötvös F, Jósvay K, Vizler C, Dombi G, et al. Functionally important amino acid residues in the transient receptor potential vanilloid 1 (TRPV1) ion channel–an overview of the current mutational data. Mol Pain. 2013;9:30.
Yang F, Zheng J. Understand spiciness: mechanism of TRPV1 channel activation by capsaicin. Protein Cell. 2017;8:169–77.
Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature. 1997;389:816–24.
Marrone MC, Morabito A, Giustizieri M, Chiurchiù V, Leuti A, Mattioli M, et al. TRPV1 channels are critical brain inflammation detectors and neuropathic pain biomarkers in mice. Nat Commun. 2017;8:15292.
Riera CE, Huising MO, Follett P, Leblanc M, Halloran J, Van Andel R, et al. TRPV1 pain receptors regulate longevity and metabolism by neuropeptide signaling. Cell. 2014;157:1023–36.
Lozano C, Córdova C, Marchant I, Zúñiga R, Ochova P, Ramírez-Barrantes R, et al. Intracellular aggregated TRPV1 is associated with lower survival in breast cancer patients. Breast Cancer (Dove Medical Press). 2018;10:161–8.
Sanchez MG, Sanchez AM, Collado B, Malagarie-Cazenave S, Olea N, Carmena MJ, et al. Expression of the transient receptor potential vanilloid 1 (TRPV1) in LNCaP and PC-3 prostate cancer cells and in human prostate tissue. Eur J Pharmacol. 2005;515:20–7.
Amantini C, Ballarini P, Caprodossi S, Nabissi M, Morelli MB, Lucciarini R, et al. Triggering of transient receptor potential vanilloid type 1 (TRPV1) by capsaicin induces Fas/CD95-mediated apoptosis of urothelial cancer cells in an ATM-dependent manner. Carcinogenesis. 2009;30:1320–9.
Amantini C, Mosca M, Nabissi M, Lucciarini R, Caprodossi S, Arcella A, et al. Capsaicin-induced apoptosis of glioma cells is mediated by TRPV1 vanilloid receptor and requires p38 MAPK activation. J Neurochem. 2007;102:977–90.
Büsselberg D, Florea AM. Targeting intracellular calcium signaling ([Ca(2+)](i)) to overcome acquired multidrug resistance of cancer cells: a mini-overview. Cancers. 2017;9:48.
Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood. 2006;107:4907–16.
Beider K, Rosenberg E, Dimenshtein-Voevoda V, Sirovsky Y, Vladimirsky J, Magen H, et al. Blocking of Transient Receptor Potential Vanilloid 1 (TRPV1) promotes terminal mitophagy in multiple myeloma, disturbing calcium homeostasis and targeting ubiquitin pathway and bortezomib-induced unfolded protein response. J Hematol Oncol. 2020;13:158.
Brookes PS, Yoon Y, Robotham JL, Anders MW, Sheu SS. Calcium, ATP, and ROS: a mitochondrial love-hate triangle. Am J Physiol Cell Physiol. 2004;287:C817–33.
Everaerts W, Gevaert T, Nilius B, De Ridder D. On the origin of bladder sensing: Tr(i)ps in urology. Neurourol Urodyn. 2008;27:264–73.
Santoni G, Farfariello V, Liberati S, Morelli MB, Nabissi M, Santoni M, et al. The role of transient receptor potential vanilloid type-2 ion channels in innate and adaptive immune responses. Front Immunol. 2013;4:34.
Park KS, Pang B, Park SJ, Lee YG, Bae JY, Park S, et al. Identification and functional characterization of ion channels in CD34(+) hematopoietic stem cells from human peripheral blood. Mol Cells. 2011;32:181–8.
Liu G, Xie C, Sun F, Xu X, Yang Y, Zhang T, et al. Clinical significance of transient receptor potential vanilloid 2 expression in human hepatocellular carcinoma. Cancer Genet Cytogenet. 2010;197:54–9.
Zhou K, Zhang SS, Yan Y, Zhao S. Overexpression of transient receptor potential vanilloid 2 is associated with poor prognosis in patients with esophageal squamous cell carcinoma. Med Oncol (Northwood, London, England). 2014;31:17.
Monet M, Lehen’kyi V, Gackiere F, Firlej V, Vandenberghe M, Roudbaraki M, et al. Role of cationic channel TRPV2 in promoting prostate cancer migration and progression to androgen resistance. Can Res. 2010;70:1225–35.
Zhang W, Chu X, Tong Q, Cheung JY, Conrad K, Masker K, et al. A novel TRPM2 isoform inhibits calcium influx and susceptibility to cell death. J Biol Chem. 2003;278:16222–9.
Narayan G, Bourdon V, Chaganti S, Arias-Pulido H, Nandula SV, Rao PH, et al. Gene dosage alterations revealed by cDNA microarray analysis in cervical cancer: identification of candidate amplified and overexpressed genes. Genes Chromosom Cancer. 2007;46:373–84.
Yamaguchi T, Yamauchi M, Sugimoto T, Chauhan D, Anderson KC, Brown EM, et al. The extracellular calcium Ca2+o-sensing receptor is expressed in myeloma cells and modulates cell proliferation. Biochem Biophys Res Commun. 2002;299:532–8.
White JP, Cibelli M, Urban L, Nilius B, McGeown JG, Nagy I. TRPV4: molecular conductor of a diverse orchestra. Physiol Rev. 2016;96:911–73.
Li P, Bian X, Liu C, Wang S, Guo M, Tao Y, et al. STIM1 and TRPV4 regulate fluid flow-induced calcium oscillation at early and late stages of osteoclast differentiation. Cell Calcium. 2018;71:45–52.
Masuyama R, Mizuno A, Komori H, Kajiya H, Uekawa A, Kitaura H, et al. Calcium/calmodulin-signaling supports TRPV4 activation in osteoclasts and regulates bone mass. J Bone Miner Res: Off J Am Soc Bone Miner Res. 2012;27:1708–21.
Shapiro IM, Layfield R, Lotz M, Settembre C, Whitehouse C. Boning up on autophagy: the role of autophagy in skeletal biology. Autophagy. 2014;10:7–19.
Duan J, Li Z, Li J, Hulse RE, Santa-Cruz A, Valinsky WC, et al. Structure of the mammalian TRPM7, a magnesium channel required during embryonic development. Proc Natl Acad Sci USA. 2018;115:E8201–10.
Yee NS. Role of TRPM7 in cancer: potential as molecular biomarker and therapeutic target. Pharmaceuticals (Basel, Switzerland). 2017;10:39.
Liu L, Wu N, Wang Y, Zhang X, Xia B, Tang J, et al. TRPM7 promotes the epithelial-mesenchymal transition in ovarian cancer through the calcium-related PI3K / AKT oncogenic signaling. J Exp Clin Cancer Re: CR. 2019;38:106.
Nadler MJ, Hermosura MC, Inabe K, Perraud AL, Zhu Q, Stokes AJ, et al. LTRPC7 is a Mg.ATP-regulated divalent cation channel required for cell viability. Nature. 2001;411:590–5.
Weinstock M, Ghobrial IM. Extramedullary multiple myeloma. Leukemia Lymphoma. 2013;54:1135–41.
de Haart SJ, Willems SM, Mutis T, Koudijs MJ, van Blokland MT, Lokhorst HM, et al. Comparison of intramedullary myeloma and corresponding extramedullary soft tissue plasmacytomas using genetic mutational panel analyses. Blood Cancer J. 2016;6:e426.
Samart P, Luanpitpong S, Rojanasakul Y, Issaragrisil S. O-GlcNAcylation homeostasis controlled by calcium influx channels regulates multiple myeloma dissemination. J Exp Clin Cancer Res: CR. 2021;40:100.
Ghobrial IM. Myeloma as a model for the process of metastasis: implications for therapy. Blood. 2012;120:20–30.
Bhutani M, Foureau DM, Atrash S, Voorhees PM, Usmani SZ. Extramedullary multiple myeloma. Leukemia. 2020;34:1–20.
Fredriksson R, Lagerström MC, Lundin LG, Schiöth HB. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol. 2003;63:1256–72.
Pin JP, Bettler B. Organization and functions of mGlu and GABA(B) receptor complexes. Nature. 2016;540:60–8.
Gurevich VV, Gurevich EV. GPCR signaling regulation: the role of GRKs and arrestins. Front Pharmacol. 2019;10:125.
Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, Kifor O, et al. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature. 1993;366:575–80.
Zhang C, Zhang T, Zou J, Miller CL, Gorkhali R, Yang JY, et al. Structural basis for regulation of human calcium-sensing receptor by magnesium ions and an unexpected tryptophan derivative co-agonist. Sci Adv. 2016;2:e1600241.
Ranieri M. Renal Ca(2+) and water handling in response to calcium sensing receptor signaling: physiopathological aspects and role of CaSR-regulated microRNAs. Int J Mol Sci. 2019;20:5341.
Whitaker M, Larman MG. Calcium and mitosis. Semin Cell Dev Biol. 2001;12:53–8.
Yamaguchi T, Chattopadhyay N, Kifor O, Butters RR Jr, Sugimoto T, Brown EM. Mouse osteoblastic cell line (MC3T3-E1) expresses extracellular calcium (Ca2+o)-sensing receptor and its agonists stimulate chemotaxis and proliferation of MC3T3-E1 cells. J Bone Miner Res: Off J Am Soc Bone Miner Res. 1998;13:1530–8.
Quarles LD, Hartle JE 2nd, Middleton JP, Zhang J, Arthur JM, Raymond JR. Aluminum-induced DNA synthesis in osteoblasts: mediation by a G-protein coupled cation sensing mechanism. J Cell Biochem. 1994;56:106–17.
Yamaguchi T, Chattopadhyay N, Kifor O, Sanders JL, Brown EM. Activation of p42/44 and p38 mitogen-activated protein kinases by extracellular calcium-sensing receptor agonists induces mitogenic responses in the mouse osteoblastic MC3T3-E1 cell line. Biochem Biophys Res Commun. 2000;279:363–8.
House MG, Kohlmeier L, Chattopadhyay N, Kifor O, Yamaguchi T, Leboff MS, et al. Expression of an extracellular calcium-sensing receptor in human and mouse bone marrow cells. J Bone Miner Res: Off J Am Soc Bone Miner Res. 1997;12:1959–70.
Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, et al. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene. 2002;21:5673–83.
Podar K, Tai YT, Davies FE, Lentzsch S, Sattler M, Hideshima T, et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood. 2001;98:428–35.
Lin HY, Harris TL, Flannery MS, Aruffo A, Kaji EH, Gorn A, et al. Expression cloning of an adenylate cyclase-coupled calcitonin receptor. Science (New York, NY). 1991;254:1022–4.
Silvestris F, Cafforio P, De Matteo M, Quatraro C, Dammacco F. Expression and function of the calcitonin receptor by myeloma cells in their osteoclast-like activity in vitro. Leuk Res. 2008;32:611–23.
Dal Maso E, Glukhova A, Zhu Y, Garcia-Nafria J, Tate CG, Atanasio S, et al. The molecular control of calcitonin receptor signaling. ACS Pharmacol Transl Sci. 2019;2:31–51.
Shyu JF, Zhang Z, Hernandez-Lagunas L, Camerino C, Chen Y, Inoue D, et al. Protein kinase C antagonizes pertussis-toxin-sensitive coupling of the calcitonin receptor to adenylyl cyclase. Eur J Biochem. 1999;262:95–101.
Ikegame M, Rakopoulos M, Zhou H, Houssami S, Martin TJ, Moseley JM, et al. Calcitonin receptor isoforms in mouse and rat osteoclasts. J Bone Miner Res: Off J Am Soc Bone Miner Res. 1995;10:59–65.
Bowler WB, Gallagher JA, Bilbe G. G-protein coupled receptors in bone. Front Biosci. 1998;3:d769–80.
Kremer R, Li J, Camirand A, Karaplis AC. Parathyroid hormone related protein (PTHrP) in tumor progression. Adv Exp Med Biol. 2011;720:145–60.
Fujita T, Meguro T, Fukuyama R, Nakamuta H, Koida M. New signaling pathway for parathyroid hormone and cyclic AMP action on extracellular-regulated kinase and cell proliferation in bone cells. Checkpoint of modulation by cyclic AMP. J Biol Chem. 2002;277:22191–200.
Cafforio P, Savonarola A, Stucci S, De Matteo M, Tucci M, Brunetti AE, et al. PTHrP produced by myeloma plasma cells regulates their survival and pro-osteoclast activity for bone disease progression. J Bone Miner Res: Off J Am Soc Bone Miner Res. 2014;29:55–66.
Pacheco PAF, Dantas LP, Ferreira LGB, Faria RX. Purinergic receptors and neglected tropical diseases: why ignore purinergic signaling in the search for new molecular targets? J Bioenerg Biomembr. 2018;50:307–13.
Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al. The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucleic Acids Res. 2014;42:D1098–106.
Qu Y, Dubyak GR. P2X7 receptors regulate multiple types of membrane trafficking responses and non-classical secretion pathways. Purinergic Signal. 2009;5:163–73.
Adinolfi E, Pizzirani C, Idzko M, Panther E, Norgauer J, Di Virgilio F, et al. P2X(7) receptor: death or life? Purinergic Signal. 2005;1:219–27.
Adinolfi E, Melchiorri L, Falzoni S, Chiozzi P, Morelli A, Tieghi A, et al. P2X7 receptor expression in evolutive and indolent forms of chronic B lymphocytic leukemia. Blood. 2002;99:706–8.
Wiley JS, Dao-Ung LP, Gu BJ, Sluyter R, Shemon AN, Li C, et al. A loss-of-function polymorphic mutation in the cytolytic P2X7 receptor gene and chronic lymphocytic leukaemia: a molecular study. Lancet (London, England). 2002;359:1114–9.
Gu B, Bendall LJ, Wiley JS. Adenosine triphosphate-induced shedding of CD23 and L-selectin (CD62L) from lymphocytes is mediated by the same receptor but different metalloproteases. Blood. 1998;92:946–51.
Acharya M, Borland G, Edkins AL, Maclellan LM, Matheson J, Ozanne BW, et al. CD23/FcεRII: molecular multi-tasking. Clin Exp Immunol. 2010;162:12–23.
Pupovac A, Geraghty NJ, Watson D, Sluyter R. Activation of the P2X7 receptor induces the rapid shedding of CD23 from human and murine B cells. Immunol Cell Biol. 2015;93:77–85.
Sarfati M, Bron D, Lagneaux L, Fonteyn C, Frost H, Delespesse G. Elevation of IgE-binding factors in serum of patients with B cell-derived chronic lymphocytic leukemia. Blood. 1988;71:94–8.
Sarfati M, Chevret S, Chastang C, Biron G, Stryckmans P, Delespesse G, et al. Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia. Blood. 1996;88:4259–64.
Barna G, Reiniger L, Tátrai P, Kopper L, Matolcsy A. The cut-off levels of CD23 expression in the differential diagnosis of MCL and CLL. Hematol Oncol. 2008;26:167–70.
Schlette E, Fu K, Medeiros LJ. CD23 expression in mantle cell lymphoma: clinicopathologic features of 18 cases. Am J Clin Pathol. 2003;120:760–6.
Walters M, Olteanu H, Van Tuinen P, Kroft SH. CD23 expression in plasma cell myeloma is specific for abnormalities of chromosome 11, and is associated with primary plasma cell leukaemia in this cytogenetic sub-group. Br J Haematol. 2010;149:292–3.
Parekh AB, Putney JW Jr. Store-operated calcium channels. Physiol Rev. 2005;85:757–810.
Pan Z, Brotto M, Ma J. Store-operated Ca2+ entry in muscle physiology and diseases. BMB Rep. 2014;47:69–79.
Zhou Y, Cai X, Nwokonko RM, Loktionova NA, Wang Y, Gill DL. The STIM-Orai coupling interface and gating of the Orai1 channel. Cell Calcium. 2017;63:8–13.
Lewis RS. Store-operated calcium channels: from function to structure and back again. Cold Spring Harbor Perspect Biol. 2020;12:a035055.
Pierro C, Sneyers F, Bultynck G, Roderick HL. ER Ca(2+) release and store-operated Ca(2+) entry – partners in crime or independent actors in oncogenic transformation? Cell Calcium. 2019;82:102061.
Lopez JJ, Jardin I, Sanchez-Collado J, Salido GM, Smani T, Rosado JA. TRPC channels in the SOCE scenario. Cells. 2020;9:126.
Ambudkar IS, de Souza LB, Ong HL. TRPC1, Orai1, and STIM1 in SOCE: friends in tight spaces. Cell Calcium. 2017;63:33–9.
Cheng KT, Ong HL, Liu X, Ambudkar IS. Contribution of TRPC1 and Orai1 to Ca(2+) entry activated by store depletion. Adv Exp Med Biol. 2011;704:435–49.
Zuccolo E, Laforenza U, Ferulli F, Pellavio G, Scarpellino G, Tanzi M, et al. Stim and Orai mediate constitutive Ca(2+) entry and control endoplasmic reticulum Ca(2+) refilling in primary cultures of colorectal carcinoma cells. Oncotarget. 2018;9:31098–119.
Yang N, Tang Y, Wang F, Zhang H, Xu D, Shen Y, et al. Blockade of store-operated Ca(2+) entry inhibits hepatocarcinoma cell migration and invasion by regulating focal adhesion turnover. Cancer Lett. 2013;330:163–9.
Stanisz H, Saul S, Müller CS, Kappl R, Niemeyer BA, Vogt T, et al. Inverse regulation of melanoma growth and migration by Orai1/STIM2-dependent calcium entry. Pigment Cell Melanoma Res. 2014;27:442–53.
McAndrew D, Grice DM, Peters AA, Davis FM, Stewart T, Rice M, et al. ORAI1-mediated calcium influx in lactation and in breast cancer. Mol Cancer Ther. 2011;10:448–60.
Motiani RK, Hyzinski-García MC, Zhang X, Henkel MM, Abdullaev IF, Kuo YH, et al. STIM1 and Orai1 mediate CRAC channel activity and are essential for human glioblastoma invasion. Pflugers Arch: Eur J Physiol. 2013;465:1249–60.
Kim JH, Lkhagvadorj S, Lee MR, Hwang KH, Chung HC, Jung JH, et al. Orai1 and STIM1 are critical for cell migration and proliferation of clear cell renal cell carcinoma. Biochem Biophys Res Commun. 2014;448:76–82.
Iamshanova O, Fiorio Pla A, Prevarskaya N. Molecular mechanisms of tumour invasion: regulation by calcium signals. J Physiol. 2017;595:3063–75.
Feske S, Wulff H, Skolnik EY. Ion channels in innate and adaptive immunity. Annu Rev Immunol. 2015;33:291–353.
Yeromin AV, Zhang SL, Jiang W, Yu Y, Safrina O, Cahalan MD. Molecular identification of the CRAC channel by altered ion selectivity in a mutant of Orai. Nature. 2006;443:226–9.
Chen YF, Chiu WT, Chen YT, Lin PY, Huang HJ, Chou CY, et al. Calcium store sensor stromal-interaction molecule 1-dependent signaling plays an important role in cervical cancer growth, migration, and angiogenesis. Proc Natl Acad Sci USA. 2011;108:15225–30.
Chen YT, Chen YF, Chiu WT, Wang YK, Chang HC, Shen MR. The ER Ca2+ sensor STIM1 regulates actomyosin contractility of migratory cells. J Cell Sci. 2013;126:1260–7.
Latour S, Mahouche I, Cherrier F, Azzi-Martin L, Velasco V, Soubeyran P, et al. Calcium independent effect of orai1 and STIM1 in non-Hodgkin B cell lymphoma dissemination. Cancers. 2018;10:402.
Yanamandra N, Buzzeo RW, Gabriel M, Hazlehurst LA, Mari Y, Beaupre DM, et al. Tipifarnib-induced apoptosis in acute myeloid leukemia and multiple myeloma cells depends on Ca2+ influx through plasma membrane Ca2+ channels. J Pharmacol Exp Ther. 2011;337:636–43.
Lepannetier S, Zanou N, Yerna X, Emeriau N, Dufour I, Masquelier J, et al. Sphingosine-1-phosphate-activated TRPC1 channel controls chemotaxis of glioblastoma cells. Cell Calcium. 2016;60:373–83.
Faouzi M, Hague F, Geerts D, Ay AS, Potier-Cartereau M, Ahidouch A, et al. Functional cooperation between KCa3.1 and TRPC1 channels in human breast cancer: role in cell proliferation and patient prognosis. Oncotarget. 2016;7:36419–35.
Guéguinou M, Harnois T, Crottes D, Uguen A, Deliot N, Gambade A, et al. SK3/TRPC1/Orai1 complex regulates SOCE-dependent colon cancer cell migration: a novel opportunity to modulate anti-EGFR mAb action by the alkyl-lipid Ohmline. Oncotarget. 2016;7:36168–84.
Elzamzamy OM, Penner R, Hazlehurst LA. The role of TRPC1 in modulating cancer progression. Cells. 2020;9:338.
Emmons MF, Anreddy N, Cuevas J, Steinberger K, Yang S, McLaughlin M, et al. MTI-101 treatment inducing activation of Stim1 and TRPC1 expression is a determinant of response in multiple myeloma. Sci Rep. 2017;7:2685.
Demaurex N, Poburko D, Frieden M. Regulation of plasma membrane calcium fluxes by mitochondria. Biochem Biophys Acta. 2009;1787:1383–94.
Duchen MR, Verkhratsky A, Muallem S. Mitochondria and calcium in health and disease. Cell Calcium. 2008;44:1–5.
Colombini M. VDAC structure, selectivity, and dynamics. Biochem Biophys Acta. 2012;1818:1457–65.
Magrì A, Reina S, De Pinto V. VDAC1 as Pharmacological target in cancer and neurodegeneration: focus on its role in apoptosis. Front Chem. 2018;6:108.
Seo JH, Agarwal E, Chae YC, Lee YG, Garlick DS, Storaci AM, et al. Mitochondrial fission factor is a novel Myc-dependent regulator of mitochondrial permeability in cancer. EBioMedicine. 2019;48:353–63.
Tan W, Colombini M. VDAC closure increases calcium ion flux. Biochem Biophys Acta. 2007;1768:2510–5.
Mazure NM. VDAC in cancer. Biochim Biophys Acta. 2017;1858:665–73.
Keinan N, Pahima H, Ben-Hail D, Shoshan-Barmatz V. The role of calcium in VDAC1 oligomerization and mitochondria-mediated apoptosis. Biochem Biophys Acta. 2013;1833:1745–54.
Weisthal S, Keinan N, Ben-Hail D, Arif T, Shoshan-Barmatz V. Ca(2+)-mediated regulation of VDAC1 expression levels is associated with cell death induction. Biochem Biophys Acta. 2014;1843:2270–81.
Shoshan-Barmatz V, Ben-Hail D. VDAC, a multi-functional mitochondrial protein as a pharmacological target. Mitochondrion. 2012;12:24–34.
Mahmoud MS, Ishikawa H, Fujii R, Kawano MM. Induction of CD45 expression and proliferation in U-266 myeloma cell line by interleukin-6. Blood. 1998;92:3887–97.
Sharaf el dein O, Gallerne C, Brenner C, Lemaire C. Increased expression of VDAC1 sensitizes carcinoma cells to apoptosis induced by DNA cross-linking agents. Biochem Pharmacol. 2012;83:1172–82.
Baughman JM, Perocchi F, Girgis HS, Plovanich M, Belcher-Timme CA, Sancak Y, et al. Integrative genomics identifies MCU as an essential component of the mitochondrial calcium uniporter. Nature. 2011;476:341–5.
De Stefani D, Raffaello A, Teardo E, Szabò I, Rizzuto R. A forty-kilodalton protein of the inner membrane is the mitochondrial calcium uniporter. Nature. 2011;476:336–40.
Marchi S, Pinton P. The mitochondrial calcium uniporter complex: molecular components, structure and physiopathological implications. J Physiol. 2014;592:829–39.
Kamer KJ, Sancak Y, Mootha VK. The uniporter: from newly identified parts to function. Biochem Biophys Res Commun. 2014;449:370–2.
Lee Y, Min CK, Kim TG, Song HK, Lim Y, Kim D, et al. Structure and function of the N-terminal domain of the human mitochondrial calcium uniporter. EMBO Rep. 2015;16:1318–33.
Orrenius S, Zhivotovsky B, Nicotera P. Regulation of cell death: the calcium-apoptosis link. Nat Rev Mol Cell Biol. 2003;4:552–65.
Landowski TH, Megli CJ, Nullmeyer KD, Lynch RM, Dorr RT. Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines. Can Res. 2005;65:3828–36.
Song IS, Kim HK, Lee SR, Jeong SH, Kim N, Ko KS, et al. Mitochondrial modulation decreases the bortezomib-resistance in multiple myeloma cells. Int J Cancer. 2013;133:1357–67.
Ria R, Vacca A. Bone marrow stromal cells-induced drug resistance in multiple myeloma. Int J Mol Sci. 2020;21:613.
Vazquez G, Wedel BJ, Bird GS, Joseph SK, Putney JW. An inositol 1,4,5-trisphosphate receptor-dependent cation entry pathway in DT40 B lymphocytes. EMBO J. 2002;21:4531–8.
Glitsch MD, Bakowski D, Parekh AB. Store-operated Ca2+ entry depends on mitochondrial Ca2+ uptake. EMBO J. 2002;21:6744–54.
Dang D, Rao R. Calcium-ATPases: Gene disorders and dysregulation in cancer. Biochem Biophys Acta. 2016;1863:1344–50.
Vangheluwe P, Sepúlveda MR, Missiaen L, Raeymaekers L, Wuytack F, Vanoevelen J. Intracellular Ca2+- and Mn2+-transport ATPases. Chem Rev. 2009;109:4733–59.
Verkhratsky A. Physiology and pathophysiology of the calcium store in the endoplasmic reticulum of neurons. Physiol Rev. 2005;85:201–79.
Brini M, Calì T, Ottolini D, Carafoli E. Calcium pumps: why so many? Compr Physiol. 2012;2:1045–60.
Yadav J, Muend S, Zhang Y, Rao R. A phenomics approach in yeast links proton and calcium pump function in the Golgi. Mol Biol Cell. 2007;18:1480–9.
Roti G, Carlton A, Ross KN, Markstein M, Pajcini K, Su AH, et al. Complementary genomic screens identify SERCA as a therapeutic target in NOTCH1 mutated cancer. Cancer Cell. 2013;23:390–405.
Varga K, Hollósi A, Pászty K, Hegedűs L, Szakács G, Tímár J, et al. Expression of calcium pumps is differentially regulated by histone deacetylase inhibitors and estrogen receptor alpha in breast cancer cells. BMC Cancer. 2018;18:1029.
Ribiczey P, Papp B, Homolya L, Enyedi Á, Kovács T. Selective upregulation of the expression of plasma membrane calcium ATPase isoforms upon differentiation and 1,25(OH)2D3-vitamin treatment of colon cancer cells. Biochem Biophys Res Commun. 2015;464:189–94.
Richardson DA, Sritangos P, James AD, Sultan A, Bruce JIE. Metabolic regulation of calcium pumps in pancreatic cancer: role of phosphofructokinase-fructose-bisphosphatase-3 (PFKFB3). Cancer Metab. 2020;8:2.
Monteith GR, Davis FM, Roberts-Thomson SJ. Calcium channels and pumps in cancer: changes and consequences. J Biol Chem. 2012;287:31666–73.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.